NRAS and cutaneous melanoma: Although MEK inhibitors might seem a rational choice for patients bearing NRAS alterations as anti-tumor activity has been reported in NRAS-mutant cutaneous melanoma patients on MEK 162 [26], experience suggests limited efficacy in such patients with other MEK inhibitors [27].